A multicentre randomised trial comparing octreotide and injection sclerotherapy in the management and outcome of acute variceal haemorrhage.

Jenkins SA, Shields R, Davies M, Elias E, Turnbull AJ, Bassendine MF, James OF, Iredale JP, Vyas SK, Arthur MJ, Kingsnorth AN, Sutton R

Gut1 Oct 1997Cited by 59 (Europe PMC)

PMID9391254PMCIDPMC1891518DOI10.1136/gut.41.4.526PepBankPUB-09391254

Source link PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In acute variceal hemorrhage, bleeding control was 85% with octreotide versus 82% with sclerotherapy, without a significant difference.
In plain wordsIn acute variceal bleeding, control was 85% with octreotide versus 82% with sclerotherapy, without a significant difference.
Peptide
Octreotide
Outcome
No significant changeControl of bleeding at 48 hours
Study
n = 150
Comparator
Emergency sclerotherapy
Outcome group
Bleeding Control · Gastrointestinal
Studied dose
50 pg/h · intravenous infusion · 48 hourAs given in this study (human).
Measurements
Controlled bleeding
62 patients
octreotide
Controlled bleeding
63 patients
sclerotherapy
Controlled bleeding
85%
octreotide
Controlled bleeding
82%
sclerotherapy
Source sentences
Summary
Overall control of bleeding and mortality was not significantly different between octreotide (85%, 62 patients) and sclerotherapy (82%, 63 patients) over the 48 hour trial period (relative risk of rebleeding 0.83; 95% confidence interval (CI) 0.38 to 1.82), irrespective of Child's grading or active…
2 context sentences(design, population, supporting numbers)
Summary · context
Consecutive patients with acute variceal haemorrhage.
Summary · context
Patients were randomised at endoscopy to receive either a 48 hour intravenous infusion of 50 pg/h octreotide (n = 73), or emergency sclerotherapy (n = 77).
Report a problemFND-0939125401
02HumanRandomized controlled trialSafety outcome
In acute variceal hemorrhage, mortality over 48 hours did not differ significantly between octreotide and sclerotherapy.
In plain wordsIn acute variceal bleeding, mortality over 48 hours did not differ significantly between octreotide and sclerotherapy.
Peptide
Octreotide
Outcome
No significant changeMortality at 48 hours
Study
n = 150
Comparator
Emergency sclerotherapy
Outcome group
Mortality · Gastrointestinal
Studied dose
50 pg/h · intravenous infusion · 48 hourAs given in this study (human).
Source sentences
Summary
Overall control of bleeding and mortality was not significantly different between octreotide (85%, 62 patients) and sclerotherapy (82%, 63 patients) over the 48 hour trial period (relative risk of rebleeding 0.83; 95% confidence interval (CI) 0.38 to 1.82), irrespective of Child's grading or active…
2 context sentences(design, population, supporting numbers)
Summary · context
Consecutive patients with acute variceal haemorrhage.
Summary · context
Patients were randomised at endoscopy to receive either a 48 hour intravenous infusion of 50 pg/h octreotide (n = 73), or emergency sclerotherapy (n = 77).
Report a problemFND-0939125402
03HumanRandomized controlled trialEfficacy outcome
In acute variceal hemorrhage, the relative risk of rebleeding with octreotide versus sclerotherapy was 0.83 (95% CI 0.38 to 1.82), within an overall difference that was not significant.
In plain wordsIn acute variceal bleeding, rebleeding risk with octreotide was not significantly different from sclerotherapy (relative risk 0.83).
Peptide
Octreotide
Outcome
No significant changeRebleeding risk
Study
n = 150
Comparator
Emergency sclerotherapy
Outcome group
Bleeding Control · Gastrointestinal
Studied dose
50 pg/h · intravenous infusion · 48 hourAs given in this study (human).
Measurements
Relative risk of rebleeding
0.83 relative risk
octreotide versus sclerotherapy
95% CI of relative risk of rebleeding
0.38 to 1.82 relative risk
octreotide versus sclerotherapy
Source sentences
Summary
Overall control of bleeding and mortality was not significantly different between octreotide (85%, 62 patients) and sclerotherapy (82%, 63 patients) over the 48 hour trial period (relative risk of rebleeding 0.83; 95% confidence interval (CI) 0.38 to 1.82), irrespective of Child's grading or active…
2 context sentences(design, population, supporting numbers)
Summary · context
Consecutive patients with acute variceal haemorrhage.
Summary · context
Patients were randomised at endoscopy to receive either a 48 hour intravenous infusion of 50 pg/h octreotide (n = 73), or emergency sclerotherapy (n = 77).
Report a problemFND-0939125403
04HumanRandomized controlled trialSafety outcome
In acute variceal hemorrhage, mortality trended higher with octreotide than sclerotherapy at 60 days (relative risk 1.91, 95% CI 0.97 to 3.78, p = 0.06).
In plain wordsIn acute variceal bleeding, mortality trended higher with octreotide than sclerotherapy at 60 days, without statistical significance.
Peptide
Octreotide
Outcome
IncreaseMortality at 60 days
Study
n = 150
Comparator
Emergency sclerotherapy
Outcome group
Mortality · Whole body
Studied dose
50 pg/h · intravenous infusion · 48 hourAs given in this study (human).
Measurements
Relative risk of dying at 60 days
1.91 relative risk
octreotide versus sclerotherapy
95% CI of relative risk of dying at 60 days
0.97 to 3.78 relative risk
octreotide versus sclerotherapy
Source sentences
Summary
During 60 days of follow up there was an overall trend towards an increased mortality in the octreotide group which was not statistically significant (relative risk of dying at 60 days 1.91, 95% CI 0.97 to 3.78, p = 0.06).
2 context sentences(design, population, supporting numbers)
Summary · context
Consecutive patients with acute variceal haemorrhage.
Summary · context
Patients were randomised at endoscopy to receive either a 48 hour intravenous infusion of 50 pg/h octreotide (n = 73), or emergency sclerotherapy (n = 77).
Report a problemFND-0939125406
05HumanNon-randomized trialSafety outcome
In acute variceal hemorrhage, pulmonary oedema was one of two major complications reported in the octreotide group.
In plain wordsIn acute variceal bleeding, pulmonary oedema was one of two major complications reported in the octreotide group.
Peptide
Octreotide
Outcome
Not applicablePulmonary oedema
Study
n = 73
Outcome group
Adverse events · Respiratory
Studied dose
50 pg/h · intravenous infusion · 48 hourAs given in this study (human).
Measurements
Major complications (pulmonary oedema and severe paralytic ileus together)
2 complications
octreotide group
Source sentences
Summary
One major complication was observed in the sclerotherapy group (aspiration) and two in the octreotide group (pulmonary oedema, severe paralytic ileus).
2 context sentences(design, population, supporting numbers)
Summary · context
Consecutive patients with acute variceal haemorrhage.
Summary · context
Patients were randomised at endoscopy to receive either a 48 hour intravenous infusion of 50 pg/h octreotide (n = 73), or emergency sclerotherapy (n = 77).
Report a problemFND-0939125404
06HumanNon-randomized trialSafety outcome
In acute variceal hemorrhage, severe paralytic ileus was one of two major complications reported in the octreotide group.
In plain wordsIn acute variceal bleeding, severe bowel paralysis was one of two major complications reported in the octreotide group.
Peptide
Octreotide
Outcome
Not applicableSevere paralytic ileus
Study
n = 73
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
50 pg/h · intravenous infusion · 48 hourAs given in this study (human).
Measurements
Major complications (pulmonary oedema and severe paralytic ileus together)
2 complications
octreotide group
Source sentences
Summary
One major complication was observed in the sclerotherapy group (aspiration) and two in the octreotide group (pulmonary oedema, severe paralytic ileus).
2 context sentences(design, population, supporting numbers)
Summary · context
Consecutive patients with acute variceal haemorrhage.
Summary · context
Patients were randomised at endoscopy to receive either a 48 hour intravenous infusion of 50 pg/h octreotide (n = 73), or emergency sclerotherapy (n = 77).
Report a problemFND-0939125405

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.